CONSUN 康 臣

康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1681)

POSITIVE PROFIT ALERT

This announcement is made by Consun Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2014, it is expected that the Group would record a significant increase in net profit for the six months ended 30 June 2014 as compared with that for the six months ended 30 June 2013, which was primarily attributable to the continued growth of sales of the Group's kidney medicines, contrast medium and other medicines during the period, which increased by more than 30% as compared with the corresponding period of last year, and the interest income of approximately RMB12,000,000 earned from placing the proceeds of the Company's initial public offering of shares on the Stock Exchange on 19 December 2013 at banks temporarily during the period.

The information set out in this announcement is only based on the information currently available to the Company and the Company's preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2014, subject to finalization and other potential adjustments (if necessary), and is not based on any figures or information audited or reviewed by the auditor or the Audit Committee of the Company. Shareholders and potential investors are advised to carefully read the interim results announcement of the Group for the six months ended 30 June 2014, which is expected to be published by the end of this month.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 5 August 2014

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.